Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Payers Move Against Avastin: California Blue Shield Halting Coverage In Breast Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Announcement follows similar moves by three smaller commercial payers earlier this year.

You may also be interested in...

Implications Of Avastin Breast Cancer Withdrawal Already Felt

Now that the FDA has pulled the plug on Avastin’s metastatic breast cancer indication, the implications for Roche may not be as far-reaching as many suspect.

NCCN Guidelines Reaffirm Support For Avastin In Metastatic Breast Cancer

The influential NCCN Clinical Practice Guidelines for Oncology should retain its recommendation supporting use of Genentech/Roche’s Avastin (bevacizumab) in metastatic breast cancer, the National Comprehensive Cancer Network expert breast cancer panel voted 24-0, with 1 abstention, at its July 10-12 meeting. NCCN recommendations are often used by payers in establishing formulary and coverage policies.

Avastin’s Breast Cancer Claim: Will FDA’s Hamburg Take A Middle Road?

FDA Commissioner Margaret Hamburg faces a decision on the future of Avastin’s (bevacizumab) first-line metastatic breast cancer claim that may not be so cut and dried as the Oncologic Drugs Advisory Committee’s unanimous vote favoring the indication’s withdrawal suggests.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts